Endocrine Society Educates Congress About the Science of PFAS Exposure

On Wednesday, November 6, the Endocrine Society hosted a congressional briefing to share the latest science with policy makers on how research conducted and funded by the National Institute of Environmental Health Sciences (NIEHS) is helping us understand and address the health effects of exposure to per- and polyfluoroalkyl substances, also known as PFAS.

The briefing was organized in collaboration with the Michael J. Fox Foundation for Parkinson’s Research and the Friends of the National Institute of Environmental Health Sciences (NIEHS) and sponsored by Representatives Dan Kildee (D-MI) and Brian Fitzpatrick (R-PA), co-chairs of the Bipartisan Congressional PFAS Task Force.

During the briefing, attendees heard from expert scientists about widespread contamination issues and diverse health effects attributed to PFAS exposure. Mark Miller, MS, MBA, PhD, chief of staff, NIEHS, gave an overview of NIEHS’ research portfolio and various other activities to help address PFAS contamination among communities.

The Society is highly involved in raising awareness about PFAS exposure and consequent health effects due to the ability of these chemicals to interfere with endocrine systems and cause disease.

Zeyan Liew, PhD, MPH, shared some of his research exploring the effects of PFAS on maternal thyroid function and potential neurodevelopmental outcomes in exposed children. “Prenatal exposures to PFAS are associated with a range of adverse health outcomes in children, including some sex-specific effects,” Liew explains. “It is critical for the Congress to hear about the latest science on these effects so that they can make informed decisions and better protect the health of their constituents.”

Endocrine Society member Abby Fleisch, MD, MPH, then shared insights gathered from her research on cohort studies exploring how PFAS may play a role in obesity and osteoporosis across the lifespan. Our research raises several important questions about the health effects of PFAS exposure – like when during the lifespan do PFAS have the strongest effects on obesity?” she says. “More NIH-funded studies are needed to answer these and many other questions.”

The briefing was extraordinarily well attended, with over 85 congressional staff from the House and Senate packing the room to learn more about an area of intense national interest. Attendees were highly engaged, staying in the room following the program to ask questions of the speakers and discuss next steps in their research programs.

Endocrine Society members Abby Fleisch, MD, MPH (center) and Zeyan Liew, PhD, MPH (right), spoke at a recent congressional briefing to share the latest science with policy makers on how research conducted and funded by the National Institute of Environmental Health Sciences (NIEHS) is helping us understand and address the health effects of exposure to PFAS.

The Society is highly involved in raising awareness about PFAS exposure and consequent health effects due to the ability of these chemicals to interfere with endocrine systems and cause disease. We also strongly support the work of the Friends of NIEHS to ensure that the NIH/NIEHS receives steady, sustainable increases in funding to advance research on PFAS and other environmental toxicants. We will continue to educate policymakers, the media, and other stakeholders about NIH’s critical role in developing scientific knowledge on these chemicals and informing regulatory activity to reduce harmful exposures.

You may also like

  • Endocrine Society Advocacy Updates

    Endocrine Society Endorses Right to IVF Act  In June 2024, the Endocrine Society endorsed the Right to IVF Act, introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA), and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF). The Right to IVF Act would help individuals and families…

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…